Deciphering the mechanism and substance basis of Dingxiang Shidi Decoction for the treatment of chemotherapy-induced nausea and vomiting by integrating mass spectrometry, network pharmacology and molecular docking.
Min Zhan, Qian Wang, Jun Yan, Qiaoxuan Zhang, Liqiao Han, Zemin Wan, Shasha Li, Xianzhang Huang
{"title":"Deciphering the mechanism and substance basis of Dingxiang Shidi Decoction for the treatment of chemotherapy-induced nausea and vomiting by integrating mass spectrometry, network pharmacology and molecular docking.","authors":"Min Zhan, Qian Wang, Jun Yan, Qiaoxuan Zhang, Liqiao Han, Zemin Wan, Shasha Li, Xianzhang Huang","doi":"10.1177/09287329251358624","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundChemotherapy-induced nausea and vomiting (CINV) remains a prevalent and debilitating side effect of cancer treatment with limited therapeutic options. Dingxiang Shidi Decoction (DXSD), a classical Chinese herbal formula, has demonstrated clinical efficacy in CINV management. However, its active components and mechanism of action require systematic investigation.ObjectiveThis study aims to elucidate the pharmacologically active constituents of DXSD and their anti-CINV mechanisms.MethodsWe employed advanced analytical techniques including UPLC-MS/MS and GC-MS to analyze the chemical components of DXSD. Network pharmacology techniques were applied to explore its pharmacological mechanisms. And molecular docking simulation was conducted to further refine the drug-target interaction.ResultsA total of 292 chemical compounds were identified in DXSD, comprising 165 water-soluble components, 56 volatile components, and 84 network database entries. By integrating 564 drug targets with 888 CINV disease targets, we identified 143 potential therapeutic targets. Further protein-protein interaction (PPI) network analysis revealed 12 key active ingredients and 13 key therapeutic targets. Enrichment analysis suggested that DXSD may reduce inflammation, modulate neurotransmitter stimulation in the gastrointestinal tract, and regulate cellular proliferation and differentiation. Notably, key active ingredients, predominantly aromatic compounds such as sabinene, (-)-α-cubebene, α-copaene, β-caryophyllene, aromandendrene, γ-muurolene, (-)-α-muurolene, α-phellandrene, α-terpinene, γ-terpinene, (+)-δ-cadinene, and Gomisin B, demonstrated significant binding affinity with multiple targets, particularly AKT1, BCL2, EGFR, MTOR, and STAT3.ConclusionsThis study reveals the active components and therapeutic mechanisms of DXSD against CINV, supporting its clinical application and demonstrating the potential of aromatherapy as an effective treatment strategy.</p>","PeriodicalId":48978,"journal":{"name":"Technology and Health Care","volume":" ","pages":"9287329251358624"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology and Health Care","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/09287329251358624","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
BackgroundChemotherapy-induced nausea and vomiting (CINV) remains a prevalent and debilitating side effect of cancer treatment with limited therapeutic options. Dingxiang Shidi Decoction (DXSD), a classical Chinese herbal formula, has demonstrated clinical efficacy in CINV management. However, its active components and mechanism of action require systematic investigation.ObjectiveThis study aims to elucidate the pharmacologically active constituents of DXSD and their anti-CINV mechanisms.MethodsWe employed advanced analytical techniques including UPLC-MS/MS and GC-MS to analyze the chemical components of DXSD. Network pharmacology techniques were applied to explore its pharmacological mechanisms. And molecular docking simulation was conducted to further refine the drug-target interaction.ResultsA total of 292 chemical compounds were identified in DXSD, comprising 165 water-soluble components, 56 volatile components, and 84 network database entries. By integrating 564 drug targets with 888 CINV disease targets, we identified 143 potential therapeutic targets. Further protein-protein interaction (PPI) network analysis revealed 12 key active ingredients and 13 key therapeutic targets. Enrichment analysis suggested that DXSD may reduce inflammation, modulate neurotransmitter stimulation in the gastrointestinal tract, and regulate cellular proliferation and differentiation. Notably, key active ingredients, predominantly aromatic compounds such as sabinene, (-)-α-cubebene, α-copaene, β-caryophyllene, aromandendrene, γ-muurolene, (-)-α-muurolene, α-phellandrene, α-terpinene, γ-terpinene, (+)-δ-cadinene, and Gomisin B, demonstrated significant binding affinity with multiple targets, particularly AKT1, BCL2, EGFR, MTOR, and STAT3.ConclusionsThis study reveals the active components and therapeutic mechanisms of DXSD against CINV, supporting its clinical application and demonstrating the potential of aromatherapy as an effective treatment strategy.
期刊介绍:
Technology and Health Care is intended to serve as a forum for the presentation of original articles and technical notes, observing rigorous scientific standards. Furthermore, upon invitation, reviews, tutorials, discussion papers and minisymposia are featured. The main focus of THC is related to the overlapping areas of engineering and medicine. The following types of contributions are considered:
1.Original articles: New concepts, procedures and devices associated with the use of technology in medical research and clinical practice are presented to a readership with a widespread background in engineering and/or medicine. In particular, the clinical benefit deriving from the application of engineering methods and devices in clinical medicine should be demonstrated. Typically, full length original contributions have a length of 4000 words, thereby taking duly into account figures and tables.
2.Technical Notes and Short Communications: Technical Notes relate to novel technical developments with relevance for clinical medicine. In Short Communications, clinical applications are shortly described. 3.Both Technical Notes and Short Communications typically have a length of 1500 words.
Reviews and Tutorials (upon invitation only): Tutorial and educational articles for persons with a primarily medical background on principles of engineering with particular significance for biomedical applications and vice versa are presented. The Editorial Board is responsible for the selection of topics.
4.Minisymposia (upon invitation only): Under the leadership of a Special Editor, controversial or important issues relating to health care are highlighted and discussed by various authors.
5.Letters to the Editors: Discussions or short statements (not indexed).